Cabergoline for Lactation Inhibition After Abortion

This trial aims to determine if cabergoline can prevent breast symptoms such as engorgement, milk leakage, and tenderness after a pregnancy ends between 12 and 18 weeks. Researchers seek to discover if cabergoline reduces these symptoms and the associated discomfort compared to a placebo. Participants will receive either cabergoline or a placebo and will report their symptoms over two weeks. This trial suits those who were pregnant for 12 to 18 weeks, are not currently breastfeeding, and can visit Maimonides Medical Center for treatment. As a Phase 2 trial, this research measures cabergoline's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.

If you are currently taking a dopamine agonist or dopamine antagonist medication, you will need to stop, as these are part of the exclusion criteria for the trial.

Research has shown that cabergoline is generally safe and well-tolerated for stopping milk production. In previous studies, common side effects included dizziness, headache, nausea, and vomiting, but these occurred infrequently. One study found that side effects were mild and similar for both cabergoline and placebo groups, suggesting the treatment rarely causes serious problems. For instance, in a review of 757 women, only 14.2% experienced side effects, with dizziness and headache being the most common.

Cabergoline is unique because it directly targets prolactin, the hormone responsible for lactation, and reduces its levels. This is different from standard treatments like bromocriptine, which also targets prolactin but has a more complex side effect profile. Researchers are excited about cabergoline because it offers a single-dose oral administration, which is more convenient and potentially more tolerable for patients. Additionally, cabergoline's targeted action provides a rapid onset of relief from symptoms like breast engorgement and tenderness, potentially improving patient comfort significantly after an abortion or pregnancy loss.

Studies have shown that cabergoline effectively prevents breast symptoms after a second-trimester abortion or pregnancy loss. In this trial, participants will receive either a single dose of cabergoline or a placebo. Research indicates that a single dose of cabergoline can reduce the likelihood of breast tenderness, swelling, and milk leakage. For example, one study found that individuals who took cabergoline experienced fewer symptoms compared to those who did not. Cabergoline lowers prolactin, a hormone responsible for milk production, which helps prevent these uncomfortable breast symptoms. Overall, cabergoline has proven to be a well-tolerated and effective option for managing these issues.⁶⁷⁸⁹¹⁰